Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer
MOH_2017-07-12_000626Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Enzalutamide + ADT with Placebo + ADT (2 arms). Started Feb 2016; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2017-07-12_000626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-12_000626.